EA200700686A1 - Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии - Google Patents

Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии

Info

Publication number
EA200700686A1
EA200700686A1 EA200700686A EA200700686A EA200700686A1 EA 200700686 A1 EA200700686 A1 EA 200700686A1 EA 200700686 A EA200700686 A EA 200700686A EA 200700686 A EA200700686 A EA 200700686A EA 200700686 A1 EA200700686 A1 EA 200700686A1
Authority
EA
Eurasian Patent Office
Prior art keywords
radioactive isotope
cytotoxic agent
combined therapy
liposomes including
liposomes
Prior art date
Application number
EA200700686A
Other languages
English (en)
Other versions
EA011715B1 (ru
Inventor
Рой Ларсен
Тора Йоханна Йонасдоттир
Original Assignee
Алгета Аса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алгета Аса filed Critical Алгета Аса
Publication of EA200700686A1 publication Critical patent/EA200700686A1/ru
Publication of EA011715B1 publication Critical patent/EA011715B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к цитотоксическим агентам, представляющим собой липосомы, где данные липосомы включают в себя раствор, содержащий по меньшей мере один альфа-излучающий радиоактивный изотоп и по меньшей мере один другой терапевтический агент, в частности химиотерапевтический агент. В данном изобретении также предложены способы получения таких цитотоксических агентов, способы лечения, особенно лечения рака, с использованием данных агентов и способы их применения в изготовлении лекарственных средств.
EA200700686A 2004-10-22 2005-10-21 Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии EA011715B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0423565.1A GB0423565D0 (en) 2004-10-22 2004-10-22 Formulation
PCT/GB2005/004074 WO2006043083A2 (en) 2004-10-22 2005-10-21 Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy

Publications (2)

Publication Number Publication Date
EA200700686A1 true EA200700686A1 (ru) 2007-10-26
EA011715B1 EA011715B1 (ru) 2009-04-28

Family

ID=33485085

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700686A EA011715B1 (ru) 2004-10-22 2005-10-21 Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии

Country Status (17)

Country Link
US (1) US20080193374A1 (ru)
EP (1) EP1812115B1 (ru)
JP (1) JP5615483B2 (ru)
KR (2) KR20070108851A (ru)
CN (1) CN101060886A (ru)
AU (1) AU2005297082B2 (ru)
BR (1) BRPI0517006A (ru)
CA (1) CA2583367C (ru)
EA (1) EA011715B1 (ru)
ES (1) ES2424844T3 (ru)
GB (1) GB0423565D0 (ru)
IL (1) IL182634A (ru)
MX (1) MX2007004542A (ru)
NO (1) NO20072529L (ru)
NZ (1) NZ582713A (ru)
WO (1) WO2006043083A2 (ru)
ZA (1) ZA200704035B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644049B1 (en) 2003-04-30 2007-09-26 Ramot at Tel Aviv University Ltd. Method and device for radiotherapy
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
IN2012DN01449A (ru) * 2009-07-17 2015-06-05 Univ Denmark Tech Dtu
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
WO2012079582A1 (en) 2010-12-14 2012-06-21 Technical University Of Denmark Entrapment of radionuclides in nanoparticle compositions
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
WO2014039874A2 (en) * 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
CA2895356A1 (en) * 2012-12-19 2014-06-26 Bayer Pharma Aktiengesellschaft Combination comprising radium-223 for the treatment of cancer
US9795621B2 (en) 2012-12-20 2017-10-24 Carnegie Mellon University Methods and materials for reducing organ transplant rejection or ischemic/reperfusion injury in a subject
EP3258917B1 (en) 2015-02-19 2022-12-21 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
US9433690B1 (en) * 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
WO2016135200A1 (en) * 2015-02-26 2016-09-01 Sciencons AS Radiopharmaceutical solutions with advantageous properties
HUE034806T2 (en) 2015-07-03 2018-02-28 Oncoinvent As Radiotherapy Particles and Suspensions
KR102560243B1 (ko) 2017-05-11 2023-07-27 알파 타우 메디컬 리미티드 근접치료 디바이스용 폴리머 코팅
AU2019247818B2 (en) 2018-04-02 2021-10-14 Alpha Tau Medical Ltd. Controlled release of radionuclides
EP4213826A1 (en) * 2020-09-15 2023-07-26 Oncoinvent AS Preparations of radium-224 and progenies for use in radionuclide therapy in combination with dna repair inhibitors
WO2022130195A1 (en) 2020-12-16 2022-06-23 Alpha Tau Medical Ltd. Diffusing alpha-emitters radiation therapy with enhanced beta treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
DE60135743D1 (de) * 2000-06-16 2008-10-23 Sloan Kettering Inst Cancer Liposomale einkapselung von alphastrahlern, und deren verwendung
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
CA2490959C (en) * 2002-07-02 2013-04-16 Board Of Regents, The University Of Texas System Radiolabeled compounds and liposomes and their methods of making and using the same
US7254229B2 (en) * 2003-03-07 2007-08-07 Legerity, Inc. Method and apparatus for an active impedance feedback
US20060228297A1 (en) * 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy

Also Published As

Publication number Publication date
KR20130019029A (ko) 2013-02-25
EP1812115A2 (en) 2007-08-01
JP2008517049A (ja) 2008-05-22
GB0423565D0 (en) 2004-11-24
NO20072529L (no) 2007-05-18
CN101060886A (zh) 2007-10-24
WO2006043083A2 (en) 2006-04-27
JP5615483B2 (ja) 2014-10-29
US20080193374A1 (en) 2008-08-14
CA2583367A1 (en) 2006-04-27
AU2005297082A1 (en) 2006-04-27
CA2583367C (en) 2014-09-16
EP1812115B1 (en) 2013-05-15
IL182634A0 (en) 2007-07-24
BRPI0517006A (pt) 2008-09-30
KR20070108851A (ko) 2007-11-13
EA011715B1 (ru) 2009-04-28
IL182634A (en) 2016-03-31
MX2007004542A (es) 2007-08-17
ZA200704035B (en) 2008-08-27
WO2006043083A8 (en) 2007-09-27
WO2006043083A3 (en) 2007-01-04
ES2424844T3 (es) 2013-10-09
AU2005297082B2 (en) 2011-11-17
NZ582713A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
HK1120427A1 (en) Anti-glypican-3 antibody
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
HK1071310A1 (en) Combination therapy for the treatment of cancer
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
ATE500832T1 (de) Kombination von zd6474 und pemetrexed
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
UY27812A1 (es) Uso de docetasel-doxorubin-ciclofosfamida como apoyo de terapias
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
NO20056170L (no) Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839
NO20056171L (no) Kombinasjonsterapi
EA200201068A1 (ru) Способ и композиция для лечения рака введением химиотерапевтических средств, вызывающих апоптоз
NO20064754L (no) Kombinasjonsterapi
MX2007003463A (es) Triciclos, su elaboracion y su uso como agentes farmaceuticos.
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
GB0223379D0 (en) Combination therapy

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU